MTOR and early-onset autosomal dominant Alzheimer disease: Dactolisib is a dual ATP competitive PI3K and mTOR inhibitor, which has been proven to have certain effects on tumors (59, 60), inflammatory diseases (61), polycystic kidney disease (62), and Alzheimer’s disease (63).